Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies?

APMIS

Volumn 121, Issue 4, 2013, Pages 257-265

  Berg, Kasper Drimer ^a   Toft, Birgitte Grønkaer ^a   Røder, Martin Andreas ^a   Brasso, Klaus ^a   Vainer, Ben ^a   Iversen, Peter ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Insignificant tumour; Predictive values; Prostate cancer; Unifocality; Unilaterality

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

AGED; BIOPSY, LARGE-CORE NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 84875685350     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02965.x     Document Type: Article

References (41)

1. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-9.
2. Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat 2007;6:91-5.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
4. Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002;60:109-14.
5. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-7.
6. Marberger M, Carroll PR, Zelefsky MJ, Coleman JA, Hricak H, Scardino PT, et al. New treatments for localized prostate cancer. Urology 2008;72:S36-43.
7. Turpen R, Rosser CJ. Focal therapy for prostate cancer: revolution or evolution? BMC Urol 2009;9:2.
8. Black P. There is no role for focal therapy in prostate cancer. Can Urol Assoc J 2009;3:331-2.
9. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9.
10. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321-30.
11. Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 2003;97:1884-93.
12. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003;61:589-95.
13. Poulos CK, Daggy JK, Cheng L. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer 2004;101:527-32.
14. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol 2000;18:2862-8.
15. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003;170:370-2.
16. Iczkowski KA, Hossain D, Torkko KC, Qian J, Lucia MS, Wheeler TM, et al. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 2008;71:1166-71.
17. Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int 2009;105: 1089-92.
18. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
19. Vainer B, Toft BG, Olsen KE, Jacobsen GK, Marcussen N. Handling of radical prostatectomy specimens: total or partial embedding? Histopathology 2011;58:211-6.
20. Epstein JI. An update of the Gleason grading system. J Urol 2010;183:433-40.
21. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
22. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121-5.
23. Vismara Fugini A, Antonelli A, Giovanessi L, Gardini VC, Abuhilal M, Zambolin T, et al. [Insignificant prostate cancer: charateristics and predictive factors.]. Urologia 2011;78:184-6.
24. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
25. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
26. Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ. Prostate cancer: the new landscape. Curr Opin Urol 2009;19:154-60.
27. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 2009;18:219-32.
28. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110:906-10.
29. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
30. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53.
31. Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007;189:323-8.
32. Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009;55:600-6.
33. Pepe P, Fraggetta F, Galia A, Grasso G, Piccolo S, Aragona F. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed? Urology 2008;72:1198-202.
34. Numao N, Kawakami S, Sakura M, Komai Y, Yokoyama M, Okada Y, et al. Patient selection for hemiablative focal therapy of prostate cancer based on extended 14- or 26-core biopsy. Eur Urol Suppl 2011;10:321-2.
35. Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, Suardi N, et al. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int 2011;108:366-71.
36. Quann P, Jarrard DF, Huang W. Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings. Int J Clin Exp Pathol 2010;3:401-7.
37. Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol 2005;174:2164-8.
38. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002;167:2032-5.
39. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010;184:131-5.
40. Van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: active Surveillance' study. BJU Int 2010;105:956-62.
41. Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int 2009;104:195-9.